<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04939090</url>
  </required_header>
  <id_info>
    <org_study_id>A222004</org_study_id>
    <secondary_id>NCI-2021-03303</secondary_id>
    <secondary_id>UG1CA189823</secondary_id>
    <nct_id>NCT04939090</nct_id>
  </id_info>
  <brief_title>Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients</brief_title>
  <official_title>A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial compares the effects of olanzapine versus megestrol acetate in treating&#xD;
      loss of appetite in patients with cancer that has spread to other places in the body&#xD;
      (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if&#xD;
      olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and&#xD;
      preventing weight loss.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary and secondary objectives of the study:&#xD;
&#xD;
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine whether olanzapine leads to greater appetite improvement from baseline in&#xD;
      cancer patients suffering from anorexia compared to megestrol acetate using the 0-10&#xD;
      numerical rating scale (NRS).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether olanzapine leads to a greater proportion of patients who report a 5%&#xD;
      or greater weight gain from baseline compared to megestrol acetate.&#xD;
&#xD;
      II. To compare change in cachexia/anorexia symptoms with olanzapine compared to megestrol&#xD;
      acetate using the Functional Assessment of Anorexia/Cachexia Treatment&#xD;
      (FAACT)-Anorexia/Cachexia Subscale (A/CS) instrument.&#xD;
&#xD;
      OUTLINE: Patient are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive olanzapine orally (PO) once daily (QD) for up to 4 weeks in the&#xD;
      absence of consent withdrawal or unacceptable toxicity.&#xD;
&#xD;
      ARM II: Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of consent&#xD;
      withdrawal or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in appetite</measure>
    <time_frame>Baseline up to 4 weeks</time_frame>
    <description>Will be compared between the two study groups (olanzapine versus megestrol acetate) using a 0-10 numerical rating scale. Will be summarized by mean (standard deviation [SD]) and median (range) by treatment arm. The difference in appetite change from baseline to 4 weeks of treatment between arms will be estimated along with a 95% confidence interval and will be compared using a t-test or Wilcoxon rank-sum test as appropriate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who report a 5% or greater weight gain</measure>
    <time_frame>Baseline up to 4 weeks</time_frame>
    <description>The proportion of patients with a 5% or greater weight gain from baseline will be calculated for each arm. The difference in proportion of patients with 5% or greater weight gain between the arms will be estimated along with a 95% confidence interval using a normal approximation of the binomial distribution and will be compared using a Chi-squared test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in well-being status and cachexia/anorexia symptoms</measure>
    <time_frame>Baseline up to 4 weeks</time_frame>
    <description>Responses to the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS) questionnaire will be scored according to the established algorithm. The total score of the FAACT-A/CS will be summarized weekly and the change from baseline to 4 weeks will be compared between the treatment arms using the same methods described for the primary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Advanced Malignant Solid Neoplasm</condition>
  <condition>Anorexia</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Arm I (olanzapine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive olanzapine PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (megestrol acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (olanzapine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (megestrol acetate)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (olanzapine)</arm_group_label>
    <arm_group_label>Arm II (megestrol acetate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women and men of reproductive potential should agree to use an appropriate method of&#xD;
             birth control throughout their participation in this study due to the teratogenic&#xD;
             potential of the therapy utilized in this trial. Appropriate methods of birth control&#xD;
             include abstinence, oral contraceptives, implantable hormonal contraceptives or double&#xD;
             barrier method (diaphragm plus condom)&#xD;
&#xD;
          -  Diagnosis of advanced cancer&#xD;
&#xD;
          -  Patient-reported 2-month weight loss of at least 5 pounds (2.3 kilograms) and/or&#xD;
             physician-estimated caloric intake of less than 20 calories/kilogram of body weight&#xD;
             per day&#xD;
&#xD;
          -  The patient must perceive loss of appetite and/or weight as a problem; and have an&#xD;
             appetite score of 4 or worse on the &quot;Please rate your appetiteâ€¦.&quot; question that&#xD;
             requires a patient response on a 0-10 numeric rating scale&#xD;
&#xD;
          -  Not receiving ongoing tube feedings or parenteral nutrition at the time of&#xD;
             registration&#xD;
&#xD;
          -  Not currently using systemic adrenal steroids (with the exception of short-term&#xD;
             dexamethasone within 3 days of chemotherapy for control of chemotherapy side effects)&#xD;
&#xD;
          -  No use of androgens, progesterone analogs, or other appetite stimulants within the&#xD;
             past month&#xD;
&#xD;
          -  Patient should not have poorly controlled hypertension or congestive heart failure at&#xD;
             registration&#xD;
&#xD;
          -  Patient should not have an obstruction of the alimentary canal, malabsorption, or&#xD;
             intractable vomiting (defined as vomiting more than 3 times per day over the preceding&#xD;
             week)&#xD;
&#xD;
          -  Not currently using olanzapine for another medical condition or had previously used&#xD;
             olanzapine for chronic nausea or for any pre-existing psychotic disorder&#xD;
&#xD;
          -  Patient should not have had a previous blood clot at any time in the past&#xD;
&#xD;
          -  No history of poorly controlled diabetes&#xD;
&#xD;
          -  No symptomatic leptomeningeal disease or known brain metastases as these patients may&#xD;
             have difficulty taking oral medications&#xD;
&#xD;
          -  No history of hypersensitivity to olanzapine or megestrol acetate&#xD;
&#xD;
          -  No COVID-19 infection in the past that, in the opinion of the treating physician, had&#xD;
             left patients with compromised taste, which has not resolved at the time of&#xD;
             registration&#xD;
&#xD;
          -  Not pregnant and not nursing, because this study involves an investigational agent&#xD;
             whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn&#xD;
             are unknown. Therefore, for women of childbearing potential only, a negative urine or&#xD;
             serum pregnancy test done =&lt; 14 days prior to registration is required&#xD;
&#xD;
          -  Age &gt;= 18 years&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2&#xD;
&#xD;
          -  Estimated life expectancy of 3 months or longer&#xD;
&#xD;
          -  Serum creatinine =&lt; 2.0 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =&lt; 3 x upper limit&#xD;
             of normal (ULN)&#xD;
&#xD;
          -  Fasting glucose &gt; 1410 mg/dl&#xD;
&#xD;
          -  Granulocytes &gt; 1000/hpf&#xD;
&#xD;
          -  No treatment with another antipsychotic agent, such as risperidone, quetiapine,&#xD;
             clozapine, butyrophenone within 30 days of enrollment&#xD;
&#xD;
          -  In order to complete the mandatory patient-completed measures, participants must be&#xD;
             able to speak and/or read English or Spanish. Sites seeking to enroll Spanish-speaking&#xD;
             patients should have access to Spanish speaking staff on site or through the use of a&#xD;
             translation service to be able to conduct the informed consent discussion in Spanish,&#xD;
             and to conduct the weekly phone calls&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric illness which would prevent the patient from giving informed consent&#xD;
&#xD;
          -  Medical condition such as uncontrolled infection (including human immunodeficiency&#xD;
             virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion&#xD;
             of the treating physician, would make this protocol unreasonably hazardous for the&#xD;
             patient&#xD;
&#xD;
          -  Patients who cannot swallow oral formulations of the agents&#xD;
&#xD;
          -  Patients with impaired decision-making capacity (such as with a diagnosis of dementia&#xD;
             or memory loss) are not eligible for this study&#xD;
&#xD;
          -  No presence of a hormone-sensitive tumor, such as breast, endometrial, or prostate&#xD;
             cancer (this exclusion criterion is intended to circumvent any confounding&#xD;
             antineoplastic effects of megestrol acetate)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aminah Jatoi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aminah Jatoi, MD</last_name>
    <phone>507-266-9160</phone>
    <email>Jatoi.aminah@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Illinois CancerCare-Bloomington</name>
      <address>
        <city>Bloomington</city>
        <state>Illinois</state>
        <zip>61704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Canton</name>
      <address>
        <city>Canton</city>
        <state>Illinois</state>
        <zip>61520</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Carthage</name>
      <address>
        <city>Carthage</city>
        <state>Illinois</state>
        <zip>62321</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Dixon</name>
      <address>
        <city>Dixon</city>
        <state>Illinois</state>
        <zip>61021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>815-285-7800</phone>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Eureka</name>
      <address>
        <city>Eureka</city>
        <state>Illinois</state>
        <zip>61530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Galesburg</name>
      <address>
        <city>Galesburg</city>
        <state>Illinois</state>
        <zip>61401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Kewanee Clinic</name>
      <address>
        <city>Kewanee</city>
        <state>Illinois</state>
        <zip>61443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Macomb</name>
      <address>
        <city>Macomb</city>
        <state>Illinois</state>
        <zip>61455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Ottawa Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Illinois</state>
        <zip>61350</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Pekin</name>
      <address>
        <city>Pekin</city>
        <state>Illinois</state>
        <zip>61554</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peru</name>
      <address>
        <city>Peru</city>
        <state>Illinois</state>
        <zip>61354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Princeton</name>
      <address>
        <city>Princeton</city>
        <state>Illinois</state>
        <zip>61356</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare - Washington</name>
      <address>
        <city>Washington</city>
        <state>Illinois</state>
        <zip>61571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>309-243-3605</phone>
      <email>andersonj@illinoiscancercare.com</email>
    </contact>
    <investigator>
      <last_name>Bryan A. Faller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Greeley Medical Center</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-956-4132</phone>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC - Ames</name>
      <address>
        <city>Ames</city>
        <state>Iowa</state>
        <zip>50010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-239-4734</phone>
      <email>ksoder@mcfarlandclinic.com</email>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Boone</name>
      <address>
        <city>Boone</city>
        <state>Iowa</state>
        <zip>50036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-956-4132</phone>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Trinity Cancer Center</name>
      <address>
        <city>Fort Dodge</city>
        <state>Iowa</state>
        <zip>50501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-956-4132</phone>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Jefferson</name>
      <address>
        <city>Jefferson</city>
        <state>Iowa</state>
        <zip>50129</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-956-4132</phone>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McFarland Clinic PC-Marshalltown</name>
      <address>
        <city>Marshalltown</city>
        <state>Iowa</state>
        <zip>50158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>515-956-4132</phone>
    </contact>
    <investigator>
      <last_name>Debra M. Prow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 17, 2021</study_first_submitted>
  <study_first_submitted_qc>June 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Anorexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

